Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the breast

- Clinical evidence of metastatic disease

- No more than 2 prior chemotherapy regimens for metastatic disease

- Prior neoadjuvant or adjuvant chemotherapy allowed*

- At least 1 prior regimen (in any setting) must have included a taxane and/or an
anthracycline

- Measurable disease, defined as ≥ 1 lesion whose longest diameter can be accurately
measured per RECIST criteria

- No nonmeasurable disease, defined as all other lesions, including small
lesions(longest diameter < 20 mm) and truly nonmeasurable lesions, including the
following:

- Bone lesions

- Leptomeningeal disease

- Ascites

- Pleural/pericardial effusion

- Inflammatory breast disease

- Lymphangitis cutis/pulmonis

- Abdominal masses that are not confirmed and followed by imaging techniques

- Cystic lesions

- Patients with HER2-positive tumors (3+ by immunohistochemistry or amplified by
fluorescent in situ hybridization [FISH]) must have received ≥ 1 prior trastuzumab
(Herceptin®)-containing regimen in either the adjuvant or metastatic setting, unless
there was a contraindication

- No known CNS metastases

- No evidence of leptomeningeal involvement

- Hormone receptor status not specified

- Male or female

- Menopausal status not specified

- ECOG performance status 0-1

- Life expectancy > 3 months

- WBC ≥ 3,000/mm³

- Absolute neutrophil count ≥ 1,500/mm³

- Platelet count ≥ 75,000/mm³

- Hemoglobin > 8.0 g/dL

- Bilirubin ≤ 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 3 times ULN

- AST and ALT ≤ 2.5 times ULN

- Creatinine ≤ 1.5 times ULN

- Urine protein:creatinine ratio < 1 OR urine protein < 500 mg by 24-hour urine
collection

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 6 months after
completion of study treatment

- No significant traumatic injury within the past 4 weeks

- No history of allergy or hypersensitivity to Chinese hamster ovary cell products or
other recombinant human antibodies, drug product excipients, or agents chemically or
biologically similar to VEGF Trap

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
the past 28 days

- No nonhealing wound, fracture, or ulcer

- No stage III or IV invasive, nonbreast malignancy within the past 5 years

- No history of lung carcinoma of squamous cell type

- No clinically significant cardiovascular disease, including any of the following:

- Cerebrovascular accident or stroke within the past 6 months

- Uncontrolled hypertension, defined as blood pressure (BP) > 150/100 mm Hg OR
systolic BP > 180 mm Hg if diastolic blood pressure < 90 mm Hg on ≥ 2 separate
occasions within the past 3 months

- Myocardial infarction, coronary artery bypass graft, or unstable angina within
the past 6 months

- New York Heart Association class III or IV cardiovascular disease

- Serious cardiac arrhythmia requiring medication

- Peripheral vascular disease ≥ grade 2 within the past 6 months

- Pulmonary embolism, deep vein thrombosis, or other thromboembolic event within
the past 6 months

- No evidence of bleeding diathesis or uncontrolled coagulopathy

- No active, unresolved infection

- No serious concurrent medical condition that would preclude study participation

- No other condition or circumstance that would preclude compliance with study
requirements

- See Disease Characteristics

- Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting allowed

- No prior bevacizumab

- More than 4 weeks since prior chemotherapy, endocrine therapy, experimental drug
therapy, or immunotherapy and recovered

- More than 4 weeks since prior major surgery or open biopsy

- More than 7 days since prior core biopsy

- More than 2 weeks since prior radiotherapy, except if to a nontarget lesion only

- Prior radiotherapy to a target lesion allowed only if there has been clear
progression of the lesion since radiotherapy was completed

- Prior single-dose palliative radiotherapy within the past 2 weeks allowed

- No concurrent major surgery

- No concurrent trastuzumab

- Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 allowed
provided the following criteria are met:

- INR in-range (usually between 2 and 3) on a stable dose of oral anticoagulant
or on a stable dose of low molecular weight heparin

- No active bleeding or pathological condition that carries a high risk of
bleeding (e.g., tumor involving major vessels or known varices)

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No concurrent participation in another investigational clinical trial

- No other concurrent chemotherapeutic agents, endocrine therapy, biologic agents,
radiotherapy, or other nonprotocol antitumor therapy